Vaxcyte enters into Master Services Agreement with Lonza for manufacturing of VAX-24 and VAX-31 components

Vaxcyte, Inc.

Agreement effective March 1, 2023, for manufacturing process development and production of polysaccharide antigens, eCRM carrier, and conjugated drug substances.
Vaxcyte owns IP directly derived from its materials or improvements to its background IP; Lonza owns generally applicable IP and improvements to its background IP.
Lonza grants Vaxcyte a non-exclusive, worldwide, fully paid-up, transferable license under new general application IP for products manufactured under the agreement.
Initial term of five years with automatic renewal for two years unless either party gives two years' non-renewal notice before the fifth anniversary.
Either party may terminate for material breach, insolvency, extended force majeure, or scientific/technical impossibility; Vaxcyte may also terminate on a project-by-project basis.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Vaxcyte, Inc. entered into Master Services Agreement for Drug Substances and Microbial Products Development and Manufacturing with Lonza Ltd valued at Vaxcyte will pay Lonza for development and manufacturing services and pass-through expenses incurred (effective 2023-03-01).

Action: entry
Agreement: supply
Counterparty: Lonza Ltd
Value: Vaxcyte will pay Lonza for development and manufacturing services and pass-through expenses incurred
Effective: 2023-03-01

Exact text from the filing

On February 28, 2023, Vaxcyte, Inc. (“ Vaxcyte ”) entered into a master services agreement for conjugated polysaccharide drug substances and microbial products development and manufacturing (the “ Master Services Agreement ”) with Lonza Ltd (“ Lonza ”), effective as of March 1, 2023 (the “ Effective Date ”), pursuant to which Lonza will perform manufacturing process development and the manufacture of components for VAX-24 and VAX-31 (formerly VAX-XP), including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.

View on SEC.gov

Browse all material agreements →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-061401

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.